---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-016263"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:22:16.168369+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NextCure discontinues NC318 program; Q3 net loss $18.9M, cash runway extended to mid‑2025

## Summary
- Discontinued NC318 development after no responses in Phase 2 monotherapy; continuing Yale combo trial.
- Cash, cash equivalents and marketable securities at Sept 30, 2022: $169.2M, down from $219.6M at Dec 31, 2021.
- Q3 2022 net loss $18.9M vs $17.9M in Q3 2021; R&D expense flat at $13.5M, G&A up to $5.7M.
- Cash runway extended by 15 months; now expected to fund operations into mid‑2025.
- Advancing NC410 Phase 1b/2 combo trial, NC525 Phase 1 expected Q1 2023, and NC762 expansion.

## SEC filing metadata
- accession: 0001558370-22-016263
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837022016263/0001558370-22-016263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837022016263/nxtc-20221103x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-016263
- JSON: https://secwatch.observer/filing/0001558370-22-016263.json
- Plain text: https://secwatch.observer/filing/0001558370-22-016263.txt

## Key facts
- Earnings Releases
  NextCure, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $18.9 million for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Net income: Net loss was $18.9 million for the quarter ended September 30, 2022
  - Result: reported results
  source text: Net loss was $18.9 million for the quarter ended September 30, 202 2, as compared with a net loss of $17.9 million for the quarter ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661059/000155837022016263/0001558370-22-016263-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.